Activity Overview
This online, on-demand virtual symposium brings together renowned experts in multiple myeloma (MM). In this educational program, these experts use real-world cases and focused data reviews to examine frontline quadruplet therapy, administration considerations for therapy, and optimal sequencing of CAR-T, bispecific, and ADC therapies for their patients, equipping clinicians with practical strategies to translate emerging evidence into individualized treatment plans for patients with MM.
This
educational activity is an archive of the live presentation held on May 15, 2026.
Target Audience
This
educational activity is directed toward hematologist-oncologists, advanced
practice providers, nurses, pharmacists, and other health care providers
involved in the diagnosis and treatment of MM.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent efficacy and safety data from pivotal trials assessing new and emerging therapies for MM
- Apply disease-specific and individual patient considerations to optimize personalized treatment planning in MM
- Assess the evolving evidence on using MRD assessments to guide the choice and duration of maintenance therapy
- Implement the latest best practices for preventing and managing treatment-related toxicities in patients with MM
Mohamad Mohty, MD, PhD
Professor of Hematology, Sorbonne University
Head, Clinical Hematology and Cellular Therapy Department
Saint-Antoine Hospital
Paris, France
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, Stemline Therapeutics, Takeda; Speakers Bureau: Janssen, Jazz Pharmaceuticals, Pfizer, Sanofi; Grant/Research Funding (to institution): Bristol Myers Squibb, Janssen, Pfizer, Sanofi
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of
Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and
Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, MN
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Arcellx, BD Biosciences, BeiGene, Bristol Myers Squibb, CVS Caremark, GSK, Janssen, K36, Moderna, Pfizer, Regeneron, Roche-Genentech, Sanofi, Siemens; Grant/Research Funding (to institution): AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, CARsgen, Gracell Biotechnologies, GSK, Janssen, Oricell Therapeutics, Roche-Genentech, Sanofi, Takeda, TeloGenomics
Suzanne Lentzsch, MD, PhD
Professor of Medicine
Columbia University
Director, Multiple Myeloma and
Amyloidosis Program
Columbia University Irving Medical
Center
New York, NY
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Alexion, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Karyopharm, Pfizer, Regeneron, Sanofi; Grant/Research Funding (to institution): Sanofi; Royalty or Patent Benefits: Anselamimab
Philippe Moreau, MD
Professor of Clinical Hematology
University Hospital of Nantes, France
Nantes, France
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Amgen, Bristol Myers Squibb, Janssen, Pfizer, Sanofi, Takeda
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence. In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information
presented and apply their own clinical judgment when considering patient care
decisions.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here